相关临床试验
121
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1845
进行中（未招募）
7
5.8%
已完成
68
56.2%
Enrolling By Invitation
1
0.8%
尚未招募
4
3.3%
招募中
20
16.5%
终止
3
2.5%
Unknown
18
14.9%
暂无批准数据
- ArrayPatch Ltd has raised €1.6 million in the first close of a €3 million seed funding round to advance ITZ-DerMap™, a novel microneedle patch for treating onychomycosis (nail fungus). - The company's proprietary DerMap™ platform features polymer-free microneedles made entirely from the drug being delivered, which dissolve upon skin penetration to release medication at the target site. - Lakeside Capital Ltd led the funding round, with additional investors including Enterprise Ireland, The Boole Investment Syndicate, and DeepIE Ventures. - The financing will enable ArrayPatch to accelerate clinical development of ITZ-DerMap™ toward clinical proof-of-concept for this transformational nail fungus treatment.
- ArrayPatch, a University College Cork spinout, won the top prize at the €800K Seedcorn awards for its DerMap microneedle technology that delivers medication through dissolving patches applied to the skin. - The company's innovative approach creates microneedles from "pure medicine" rather than traditional polymers, achieving 56 times higher drug delivery levels than oral and topical treatments in animal trials for nail fungal infections. - ArrayPatch is raising €3M in seed funding and plans first-in-human trials in Q1 2025, targeting a market worth $6.2 billion for nail fungal infections alone by 2027. - The platform technology has potential applications beyond nail infections, including skin cancer, diabetes, migraines, and hormone replacement therapy, representing a combined market opportunity of $70 billion.
- German pharmaceutical CDMO Aenova announces significant expansion of its Killorglin, Ireland facility to develop innovative drug delivery systems focusing on spray-dried amorphous solid dispersions and inhalation powders. - The strategic investment targets improving bioavailability of poorly soluble drugs, which constitute approximately 80% of compounds in global research pipelines. - The expansion will create 10 new positions in research and development, pharmaceutical technology, and analytics at the facility that currently employs 68 people. - The new spray drying technology aims to help pharmaceutical customers bring their products to market faster by addressing critical bioavailability challenges.
